This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
After calling Rockville, Maryland home for more than eight years, pharma giant G...
Farallon presses Astellas to cut costs and overhaul drugs research in latest sha...
Elon Musk is extending his power over the federal workforce after President Trum...
TUESDAY, Feb. 11, 2025 -- Among simple congenital heart diseases (CHD), patent ...
STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX),...
So far in 2025, the year’s biggest cultural events have served as launchpads for...
The neurostimulation company, based outside Minneapolis, said in a filing that i...
This week in health policy and politics: Reviving a defunct vaccine panel, NIH f...
“Authoritarian regimes often rely on doctors and other health workers to provide...
After an apparent accidental early release, Pfizer has revealed phase 1 data sho...
The FDA earlier this month issued separate warning letters to Chinese drug ingre...
Healthcare company is trying to reorganise and rebuild its medical technology di...
A federal judge on Tuesday ordered government agencies to restore public access ...
After an apparent accidental early release, Pfizer has revealed phase 1 data sho...
Drugmakers — major beneficiaries of NIH-backed university research — have been l...
TUESDAY, Feb. 11, 2025 -- The 18-gene MyProstateScore 2.0 (MPS2) test using fir...
TUESDAY, Feb. 11, 2025 -- Better labor and delivery staffing during labor predi...
TUESDAY, Feb. 11, 2025 -- Some risk factors for epithelial ovarian cancer are m...
TUESDAY, Feb. 11, 2025 -- From 2011 to 2023, there was an increase in early adu...
TUESDAY, Feb. 11, 2025 -- Rates of major bleeding and intracranial hemorrhage a...
TUESDAY, Feb. 11, 2025 -- The proportion of pediatric fatalities from weather e...
TUESDAY, Feb. 11, 2025 -- Age differences are seen in the efficacy of treatment...
TUESDAY, Feb. 11, 2025 -- Adverse childhood experiences (ACEs) in the year befo...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzhei...